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Abstract
Aims: Research into right ventricular (RV) physiology and identification of pathomechanisms underlying RV
failure have been neglected for many years, because function of the RV is often considered less important for
overall hemodynamics and maintenance of blood circulation. In view of this, this study focuses on identifying
specific adaptive mechanisms of the RV and left ventricle (LV) during a state of chronic nitric oxide (NO)
deficiency, one of the main causes of cardiac failure. NO deficiency was induced in rats by L-NAME feeding
over a 4 week period. The cardiac remodeling was then characterized separately for the RV/LV using quan-
titative real-time polymerase chain reaction, histology, and functional measurements. Results: Only the RV
underwent remodeling that corresponded morphologically and functionally with the pattern of dilated cardio-
myopathy. Symptoms in the LV were subtle and consisted primarily of moderate hypertrophy. A massive
increase in reactive oxygen species (ROS) (+4.5– 0.8-fold, vs. control) and a higher degree of oxidized
tropomyosin (+46%– 4% vs. control) and peroxynitrite (+32%– 2% vs. control) could be identified as the cause
of both RV fibrosis and contractile dysfunction. The expression of superoxide dismutase-2 was specifically
increased in the LV by 51%– 3% and prevented the ROS increase and the corresponding structural and
functional remodeling. Innovation: This study identified the inability of the RV to increase its antioxidant
capacity as an important risk factor for developing RV failure. Conclusion: Unlike the LV, the RV did not
display the necessary adaptive mechanisms to cope with increased oxidative stress during a state of chronic NO
deficiency. Antioxid. Redox Signal. 23, 1220–1232.
Introduction
For a long time, the right ventricle (RV) was viewed toplay a marginal role in the maintenance and stability of
global hemodynamics of adults. As a consequence, research
into RV physiology, including the identification of specific
pathomechanisms, has been a neglected subject of study, and
only a few randomized clinical trials on RV failure have been
carried out (29).
In this way, the range of therapeutic interventions avail-
able for RV failure corresponds largely to those for left
ventricular (LV) failure. These interventions primarily tar-
get vasodilatation and thus at reducing cardiac afterload
(34). However, the National Heart, Lung, and Blood In-
stitute described the situation in a special report on the RV
as follows: ‘‘. right ventricular failure cannot be under-
stood simply by extrapolating data and experience from left
ventricular failure.The right ventricle is different from the
left ventricle’’(50).
The inadequate understanding of the RV pathophysiology,
however, stands in sharp contrast to the frequency of RV
failure, which does not differ from that of LV failure. The
results of the CORE trial have also demonstrated that isolated
RV failure or involvement of the RV in the cardiac symptoms
1Physiologisches Institut, Justus-Liebig-Universita¨t Gießen, Giessen, Germany.
2Fraunhofer-Institut fu¨r Zelltherapie und Immunologie, Leipzig, Germany.
3Pharmahungary Group, Szeged, Hungary.
4Cardiovascular Research Group, Department of Biochemistry, University of Szeged, Szeged, Hungary.
5Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
ANTIOXIDANTS & REDOX SIGNALING
Volume 23, Number 15, 2015
ª Mary Ann Liebert, Inc.
DOI: 10.1089/ars.2014.6139
1220
D
ow
nl
oa
de
d 
by
 S
EM
M
EL
W
EI
S 
U
N
IV
 O
F 
M
ED
IC
IN
E 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 1
2/
04
/1
9.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
is associated with a poorer prognosis compared with purely
LV dysfunction (35).
However, the well-documented molecular and cellular
mechanisms identified in the LV cannot readily be translated
to the right heart. This situation can be substantiated by the
specific cardiogenesis of the RV, the cellular origin of which
can be traced back to the secondary or anterior heart field
along with the septum and the outflow tract. In contrast, the
atria and the entire LV originate from a population of pro-
genitor cells that formed the primary heart field (49, 51).
At a molecular and cellular level, the pathogenesis and
progression of chronic cardiac insufficiency can often be
attributed to a reduced bioavailability of nitric oxide (NO),
increased radical stress, and cardiac fibrosis (13, 27, 31).
In particular, the increased rate of cardiovascular events
associated with chronic kidney diseases, type 2 diabetes
mellitus, or women after menopause is ascribed to a general
deficit of NO, among other factors (7, 48).
The effects of NO within the cardiovascular system are not
solely attributed to its vasodilatory and thus antihypertensive
properties. NO interacts far more ubiquitously at cellular and
subcellular levels, in part, by nitrosation of cystein residues
within signaling pathways of the renin-angiotensin-aldosterone
system (RAAS), the sympathetic nervous system, and the mi-
tochondria, and thus directly and indirectly influences the
function and structure of the myocardium (21, 39, 45).
The primary research aim of this study is to identify the key
enzymes and pathomechanisms that are specific and are
regulated differently for the RV and LV during a state of
systemic NO deficiency.
Chronic NO deficiency was induced in this study in female
adult rats by feeding them the NOS inhibitor L-NAME over a
period of 4 weeks. The effects of reduced NO levels on mo-
lecular and cellular parameters were studied for both ventricles.
During long-term application of L-NAME, the symptoms
in experimental animals could only, in part, be attributed to
the immediate reduction in the NO-dependent effects. Over
the further course, a chronic deficiency in NO led to increased
formation of reactive oxygen species (ROS) that not only
favor the development of hypertension but also directly affect
cell and organ functions. For this reason, the pure L-NAME
substitution was supplemented by two additional applica-
tions. One treatment group also received the angiotensin-
converting enzyme (ACE)-inhibitor captopril, while another
was given the radical scavenger and superoxide dismutase
(SOD)-mimetic tempol in the form of a therapeutic inter-
vention in the third and fourth week of L-NAME application.
Along with its interaction with the RAAS and the subsequent
reduction in angiotensin-II-dependent effects, captopril also
has direct antioxidant properties via a cleavable sulfhydryl
group (36). The use of tempol allowed the identification of
protective effects that can be attributed solely to a reduction
in ROS.
Signal mechanisms and their effect on the contractile be-
havior after chronic exposure to L-NAMEwere also analyzed
in vitro in cardiomyocytes isolated from the RV or LV in-
dependent of systemic influences and blood pressure.
Results
Effect of L-NAME on systemic hemodynamics
The systolic blood pressure averaged 126– 7mm Hg with
no group differences between all test groups at the start of the
experimental protocol. This value did not change throughout
the entire course of the experiment for the animals in the
control group. In the L-NAME group (L), systolic blood
pressure increased to 173– 7mm Hg after 4 weeks. On ad-
dition of the ACE-inhibitor captopril to the L-NAME feed
after 2 weeks of treatment (LC) for the remaining 2 weeks,
the blood pressure fell from 159 – 5mm Hg (after 2 weeks of
L-NAME) to 135– 5mm Hg at 4 weeks. The supplemental
application of the SOD-mimetic tempol (LT) did not result in
a fall in blood pressure but prevented a further increase
during the last 2 weeks of the treatment period (161– 4mm
Hg). The heart rate did not change significantly in the entire
collective throughout the observation period (Supplementary
Fig. S1 and Supplementary Table S1; Supplementary Data
are available online at www.liebertpub.com/ars).
Consequences of chronic NO deficiency
on the cardiac remodeling
The wet weights of the RV and LV were standardized to
the body weight (BW) of the particular animal. Compared
with the control group, the animals in the L and LT groups
developed low-grade LV hypertrophy based on a moderate
increase in the LV/BW ratio. Captopril normalized the ratio
to the level of the control animals (Fig. 1A).
No significant difference could be detected compared with
the drinking-water controls for the RV/BW ratio independent
of the particular application scheme (Fig. 1A).
The raw data obtained for BW, the RV and LV, and lungs
and kidneys are listed in Supplementary Table S2.
However, the geometry of the RV changed in L-NAME-
fed animals and corresponded to the clinical picture of dilated
cardiomyopathy. The supplemental application of captopril or
tempol was able to positively affect the structural remodeling
of the RV—the RV dilatation was reduced, and the decrease in
the wall thickness was almost prevented (Fig. 1B, C).
On a molecular level, the remodeling of the RV and LV was
characterized by re-expression of fetal genes. Brain natriuretic
peptide and myosin heavy-chain beta were induced to a com-
parable level by L-NAME in both the RV and the LV. The
induction of atrial natriuretic peptide (ANP), which is primarily
re-expressed in response to cardiac pressure load, was increased
only in the LV by 7.8– 1.3 fold (Supplementary Fig. S2).
Functional consequences of the structural remodeling
The consequences of the L-NAME-induced remodeling on
cardiac function were analyzed at the end of the 4-week
Innovation
The results of the study demonstrate the inability of the
right ventricular (RV) to cope with oxidative stress caused
by a chronic deficiency in nitric oxide. The limited po-
tential of the RV to increase its endogenous antioxidive
capacity must be taken into consideration during the tar-
geted development of new treatment stategies for RV in-
sufficiency. The central role of the RV and its frequent
involvement in numerous cardiovascular conditions un-
derscore the necessity of viewing the RV pathophysiology
as an independent entity, as it cannot simply be deduced
from observations of the left ventricle.
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substitution using a Millar tip catheter that was advanced on
the right side to the RV via the jugular vein and atrium. The
stabilized signal was then recorded continuously over a pe-
riod of 30min.
The peak RV pressure was reduced as a result of the L-
NAME application and was affected only by captopril treat-
ment. However, both therapy strategies significantly improved
the RV dp/dt max or RV dp/dt min and thus specifically re-
duced the contractile dysfunction of the RV (Table 1).
As the cardinal symptomof impairedRV function, the blood
accumulation was determined using the liver wet weight (LW)
and the liver transaminases glutamate-oxaloacetate transami-
nase/glutamate-pyruvate transaminase (GOT/GPT). In animals
fed L-NAME, the LW/BW ratio increased by 9.2%– 0.6% (C
vs. L, 29.4 g/kg vs. 32.1 g/kg, p= 0.10) while the transaminases
rose by 14.8%– 1.7% (C vs. L, 85.8U/L vs. 98.4U/L,p= 0.01).
The LV function, represented by the LV-developed pres-
sure (LVDP), was determined using a balloon catheter. Re-
gardless of the particular application scheme, no significant
differences in the LVDP, the LV dp/dt max, or LV dp/dt min
could be detected (Supplementary Table S3). Uniform lung
wet weights largely rule out a restrictive functional disorder
(Supplementary Table S2).
Regulation of the ROS in the right and left ventricles
As previously stated in the introduction, chronic deficiency
in NO is often associated with an increase in oxidative stress.
The fluorescence microscopy images of the dihy-
droethidium (DHE) staining showed only a slight radical load
for the LV independent of the particular application scheme
with no significant differences between the treatment groups.
In contrast to this, the RV had an elevated radical load even
in untreated controls compared with the LV, and this was
further increased till 4.5 – 0.8-fold during L-NAME substi-
tution. The two therapy options, captopril and tempol, sig-
nificantly reduced the concentration of ROS in the RV to a
comparable level (Fig. 2A, B).
It could already be seen that an increased accumulation of
ROS contributes to contractile dysfunction by oxidative
modification of tropomyosin (Tm) (14, 15). The formation of
disulphide cross-bridges (DCB) at the level of cystein resi-
dues leads to an enhanced dimerization of Tm, which could
be detected as high-molecular-weight peptide (*80 kDa)
under non-reducing conditions in immunoelectrophoresis. L-
NAME application did not have any effects on DCB for-
mation in the LV; however, in the RV, a significant increase
in cross-linking processes was detected, leading to a
46% – 4% increase in oxTm/Tm ratio (Fig. 3A, B).
Given the specific changes in oxidative stress measured by
DHE staining, a specific powerful oxidant species, perox-
ynitrite (ONOO-), was quantified in the tissues from the RV
and LV. The formation of ONOO- is based on the reaction
between ROS and NO. The molecule itself does not have any
free radical properties, but it can dissociate rapidly into
highly reactive decomposition products.
Comparable to the results obtained for radical staining, no
group difference could be detected for the LV concentration
of ONOO-. Likewise, the RV had a higher concentration of
ONOO- compared with the left even in the control group. L-
NAME substitution led to a further significant increase in
peroxynitrite in the RV that could be reduced by tempol to the
level of the controls. Captopril, by contrast, led to an addi-
tional increase in the ONOO- concentration in the RV
myocardium in the LC group (Fig. 4).
The concentration of malondialdehyde (MDA) in the blood
plasmawas determined as a general indicator of oxidative stress.
The 4-week application of L-NAME led to a 24.2%– 4.9% (C
vs. L, p<0.05) increase in plasma MDA levels.
To identify a potential mechanism that explains the dif-
ferent formation in ROS in both ventricles, the expression
pattern of antioxidative enzymes was analyzed. In their role
as oxidoreductases, SODs catalyze the conversion of super-
oxide into hydrogen peroxide (H2O2) and oxygen and thus
perform important antioxidant functions. The expression
patterns of the three isoforms SOD1, 2, and 3 were each
determined separately for the RV and LV of the C and L
groups. Only the expression of SOD2 was specifically in-
creased in the LV of L-NAME-substituted animals by
51% – 3%. In contrast, this isoform was downregulated in the
RV by 30%– 4%. No significant changes could be detected in
FIG. 1. L-NAME induced changes in cardiac remodel-
ing. (A) Effects of the different treatment strategies on
myocardial hypertrophy. The wet weight of the right ven-
tricle (RV) and left ventricle (LV) were normalized to the
body weight (BW) of the particular animal. Data are
means – S.D. of n = 8 hearts. (B) Representative images of
horizontal heart sections from each treatment group. The
geometry of the RV changed in L-NAME fed animals and
corresponded with the pattern of dilated cardiomyopathy.
(C) Endocardial surface area of the RV was determined
from histological sections. Data are means – SD of n = 5
hearts. *p < 0.05 versus control, #p < 0.05 versus L-NAME.
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the expression of SOD1 and SOD3 (Fig. 5A). The selective
upregulation of SOD2 in the LV of animals fed L-NAMEwas
then confirmed in Western blots (Fig. 5B, C).
An increase in the expression of the transcription factors
PGC-1a and nuclear respiratory factor-2 (Nrf-2), which are
involved in the regulation of SOD2, was only seen in the LV
of the L group. Other downstream targets of Nrf-2 such as
glutamate-cysteine ligase, catalytic subunit (Gclc), and
thioredoxin reductase 1 (TXNRD1) were also selectively
induced in the LV in animals fed L-NAME (Fig. 6A–D).
The catalase, which is also an oxidoreductase that converts
any H2O2 that accumulates to oxygen and water, was upre-
gulated only in the LV similar to SOD2. L-NAME had no
effect on the expression of the glutathione peroxidase (Gpx)
in either the RV or the LV (Fig. 6E, F).
That there is no change in the expression of themitochondrial
uncouplers UCP2 and UCP3 as well as the hydroxyacyl-CoA
dehydrogenase, alpha subunit (HADHA) of the trifunctional
protein (MTP) and the transcription factor Nrf-1 indicates that
applying L-NAME has no effect on the mitochondrial biogen-
esis in either the RV or the LV (Supplementary Fig. S3A–D).
Of the two subunits of NADPH oxidase, p22phox and
NOX2, only the expression of NOX2 was increased in the LV
of rats fed L-NAME (Fig. 6G, H).
Effect of L-NAME on cell shortening and SOD2
expression in isolated cardiomyocytes
To investigate the effect of L-NAME on the contractile be-
havior and SOD2 expression at a cellular level, cardiomyocytes
FIG. 2. (A, B) Generation of
superoxide in right and left ven-
tricles. Dihydroethidium (DHE)
staining was performed to measure
the formation of reactive oxygen
species in heart tissue from RV and
LV of all treatment groups (control
[C], L-NAME [L], L-NAME plus
captopril [LC] and L-NAME plus
tempol [LT]). Slides were imaged
by confocal microscopy using an
excitation wavelength of 488 nm
and an emission wavelength of
540 nm. Data are means–SD of
n= 5 hearts. *p< 0.05 versus con-
trol, #p< 0.05 versus L-NAME.
Table 1. Heart Rate and Right Ventricular Contractility Assessment In Vivo Under Anesthesia
Heart rate
(bpm)
RVSP
(mm Hg)
RVEDP
(mm Hg)
RV dp/dt max
(mm Hg/s)
RV dp/dt min
(mm Hg/s)
Control (C) 422– 27 37.0 – 5.4 2.6 – 1.6 2292– 355 - 2105 – 395
L-NAME (L) 391– 25 30.7 – 4.6a 0.9 – 2.2 1608– 98a - 1363 – 136a
L-NAME + captopril (LC) 397– 28 35.9 – 1.0 1.8 – 0.2 1925– 109a,b - 1486 – 82a,b
L-NAME + tempol (LT) 425– 24 30.5 – 1.9a 1.4 – 1.1 1929– 47a,b - 1737 – 90a,b
Changes in RV contractility after 4 weeks. Rats were given pure drinking water (C) n = 10, L-NAME (L) n = 9, L-NAME plus captopril
(LC) n = 5 or L-NAME plus tempol (LT) n = 6. Data are means – SD.
ap < 0.05 versus control.
bp < 0.05 versus L-NAME.
bpm, beats per minute; RV, right ventricle; RVEDP, right ventricular end-diastolic pressure; RVSP, right ventricular systolic pressure.
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were isolated separately from the RV and LV of untreated rats
and incubated for 24 h with L-NAME. Compared with un-
treated control cells, L-NAME led to a significant reduction in
the relative cell shortening only in the RV myocytes. The ex-
pression of SOD2 corresponded to the in vivo results previously
described (Fig. 7A–C). Accordingly, L-NAME led to an in-
crease in mitochondrial ROS formation only in RV myocytes
as detected by mitochondria-targeted superoxide fluorescent
indicator MitoSOX Red (Supplementary Fig. S4).
The cell shortening seen in the LV cardiomyocytes was
significantly reduced if the myocytes incubated with L-
NAME were also incubated with the translation inhibitor
cycloheximide, the transcription inhibitor actinomycin D, or
the Sirt1 inhibitor Ex-527 (Fig. 7D). Under these conditions,
the induction of the SOD2 expression failed to materialize
(Fig. 7A, B). The MAP kinase inhibitor PD98059 did not
have any effect on the cell contraction.
Effect of L-NAME on the cardiac remodeling
of the extracellular matrix
Finally, the development and induction of cardiac fibrosis
was analyzed in response to the different level of ROS in the
RV and LV.
The causal involvement of the cytokine transforming
growth factor beta1 (TGF-beta1) in the progression of
chronic cardiac insufficiency has already been well docu-
mented. It also plays a critical role in the development and
maintenance of cardiac fibrosis.
The expression patterns for TGF-beta1 and the extracellular
matrix proteins collagen I and collagen III were analyzed sep-
arately for the RV and LV using real-time reverse transcription
polymerase chain reaction (RT-PCR). In the LV, only the
FIG. 3. Conformational changes of tropomyosin (Tm)
induced by oxidative stress. (A)Quantification of disulphide
cross-bridge formation in tropomyosin (Tm) under non-re-
ducing conditions. Oxidativemodification of Tm (oxTm) leads
to dimerization of the protein and was detected as a high-
molecular-weight peptide of*80kDa. (B) Protein expression
was analyzed in the RV and LV of control (C) and L-NAME
fed animals (L). Results are given as ratio of oxTm toTm.Data
are means–SD of n= 4 hearts. *p< 0.05 versus control.
FIG. 4. L-NAME induced changes in the formation of
peroxynitrite (ONOO2). ONOO- was measured in heart
tissue from RV (gray bars) and LV (white bars) of all treat-
ment groups (control [C], L-NAME [L], L-NAME plus cap-
topril [LC], and L-NAME plus tempol [LT]). Average LV
concentration of ONOO- was 0.65–0.21ng/mg protein. Va-
lues of RV are displayed as percent of LV. Data are means–
SD of n= 4 hearts. *p<0.05 versus LV.
FIG. 5. Expression pattern of superoxide dismutases
(SOD) in right and left ventricles. (A) The expression for
SOD1, SOD2, and SOD3 was analyzed separately for the RV
and LV of drinking-water controls and L-NAME-fed animals.
Results are displayed as fold change for each isoform normal-
ized to the control group (dashed line). The expression of
hypoxanthine-guanine phosphoribosyltransferase (HPRT) was
used for normalization. Data are means–SEM of n=8 hearts.
(B) Representative immunoblots indicating SOD2 immunore-
activity in the RV and LV from control (C) and L-NAME (L)-
treated animals. SOD2 values were normalized to GAPDH
levels. (C)Densitometric analysis of immunoblot bands. SOD2
was significantly increased in the LV from L-NAME fed ani-
mals (gray bar) compared with control animals (white bar).
Data are means–SD of n=5 hearts. *p<0.05 versus control.
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expression of TGF-beta1 was reduced in L-NAME fed animals
by 19%–3% compared with their drinking-water controls. In
the LC and LT groups, no change could be detected in the
expression of any of the genes investigated. In contrast to the
normal finding in the LV, TGF-beta1was upregulated in the RV
in the L group by 102%–6%. The expression of collagen I was
increased by 156%–16%, and that of collagen III was increased
by 280%– 26%. Both the increase in the TGF-beta1 and the
induction of the two collagen isoforms could be significantly
reduced by captopril and tempol (Fig. 8A–C).
The massive upregulation of the collagen in the RV of L-
NAME-fed animals could subsequently be confirmed using
Sirius Red staining in histological sections. Qualitatively, the
areas close to the interventricular septum were particularly
affected by an increased incorporation of extracellular matrix
proteins. Localization of the fibrosis along the RV circum-
ference was limited primarily to endocardial and epicardial
compartments (Fig. 8D, E).
However, when the antihypertensive hydralazine was
combinedwith L-NAME after 2 weeks of L-NAME treatment,
the blood pressure fell from 160– 6mm Hg (after 2 weeks of
L-NAME) to 126– 5mm Hg. However, due to the inability of
hydralazine to prevent L-NAME-inducedO2
- production, the
hearts from this group also displayed a significant upregulation
of TGF-beta1 only in the RV (Supplementary Fig. S5).
The structural remodeling of the RV and LV
in eNOS-/ - mice
To validate results obtained from L-NAME experiments,
eNOS-/- mice were used as another model for a chronic
deficiency in NO. Comparable to the mRNA expression
pattern in the RV and LV of L-NAME fed animals, SOD2
was upregulated only in the LV of eNOS-/- mice, whereas
the expression of TGF-beta1 and collagen I did not change in
the LV but was significantly increased in the RV (Supple-
mentary Fig. S6).
Discussion
The state of chronically reduced bioavailability of NO is a
risk factor for the entire cardiovascular system, which can be
attributed to the increased hemodynamic, oxidative, and fi-
brotic stress. In this study, the conditions were created for a
corresponding scenario in 3-month-old female Wistar rats by
feeding them the nonspecific NOS inhibitor L-NAME. Once
the 4-week treatment period was complete, the cardiac re-
modeling was characterized separately for the RV and LV
while considering the structural and functional adaptive re-
sponses.
Unlike the LV, the RV did not display the necessary
adaptive mechanisms to cope with increased oxidative stress,
the main and new finding of this study. The radical load
induced by L-NAME in the RV myocardium led to the for-
mation of a dilated cardiomyopathy with pronounced con-
tractile dysfunction and cardiac fibrosis. The endogenous
antioxidant potential prevented a corresponding structural
and functional remodeling in the LV. Using adjuvant therapy
with the SOD-mimetic tempol or captopril, which also has an
antioxidative effect, the vicious cycle of free radical gener-
ation, fibrosis, and contractile dysfunction could be disrupted
in the RV. Using the model of isolated cardiomyocytes, it
FIG. 6. Regulation of genes involved in redox homeostasis and antioxidative defense. The expression of mRNA was
analyzed in the RV and LV of control (C) and L-NAME (L)-fed animals. The transcription factors (A) PGC-1a and (B) nuclear
respiratory factor-2 (Nrf-2) aswell as their downstream targets (C) glutamate cysteine ligase (Gclc) and (D) thioredoxin reductase
1 (TXNRD1)were selectively induced in theLVofL-NAMEfed animals.L-NAMEalso induced the expressionof (E) catalase in
the LVbut had no effect on the expression of (F) glutathione peroxidase 1 (Gpx1). Expression of (G) p22phoxwas not influenced
but that of (H) NOX2 was induced by L-NAME in the LV. Data are means–SD of n= 8 hearts. *p< 0.05 versus control.
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could also be shown that the specific endogenous properties
of RV myocytes were critically involved in the diagnosed
RV dysfunction.
In general, the RV is characterized by a high degree of
plasticity. If it detects systemic perfusion due to a patent
arterial duct while still in the uterus, this function is trans-
ferred from birth onward to the left half of the heart (26). The
myocardium of the RV adjusts postpartum to its new function
and is characterized from this point on by a high degree of
elasticity due to the low wall thickness. The structure and
geometry are designed for volume work and can adjust more
easily to an increased preload than to an increase in the
afterload (26).
The contribution of the RV to maintaining appropriate blood
circulation was underestimated for many years, and research
into its specific physiology was neglected. However, its im-
portance for the entire cardiovascular system can be explained
solely by the fact that physical performance correlates more
strongly with RV function than with LV function (4).
Gulati et al. diagnosed an RV dysfunction in 30% of pa-
tients with nonischemic dilated cardiomyopathy and identi-
fied this as an independent risk factor that was associated with
a fourfold higher total mortality (24). Comparable results
were obtained by Mehta et al. for the involvement of the RV
in LV myocardial infarction, and they describe an increased
rate of postischemic complications and fatalities (35). For
pulmonary hypertension, the right heart function was even
identified as a critical predictor for premature mortality, al-
though the RV has the potential to adjust in the long term to a
pathologically increased afterload by means of compensatory
hypertrophy (25).
The chronic application of L-NAME in drinking water is
an established model for arterial hypertension. The increased
vascular resistance and the vascular remodeling are induced
by a lowering of the NO level and activation of the systemic
and local renin–angiotensin systems as well as greater oxi-
dative stress (23). The therapeutic use of the ACE-inhibitor
captopril led to a significant fall in the systolic blood pres-
sure, while the antioxidant tempol was only able to prevent a
further increase in the last 2 weeks.
The involvement of ROS in cardiovascular effects induced
by L-NAME has already been demonstrated by Kumar et al.,
who were even able to significantly lower the blood pressure
using oral application of syringic acid, a naturally occurring
antioxidant (30). A reduction of oxidative stress through se-
lective inhibition of xanthine oxidase by allopurinol had no
effect on hypertension but significantly improved the L-
NAME-induced cardiac remodeling (28). The significantly
elevated plasma MDA levels, which can be attributed to an
increase in the lipid peroxidation, suggest that chronic ap-
plication of L-NAME also led to an increase in radical stress
in the model used here.
However, histological and molecular results indicate that
the cause of the RV dysfunction is a massive increase in
oxidative stress. NADPH oxidase, xanthine oxidase, and the
renin–angiotensin system were identified as potential sources
of excessive radical production under chronic L-NAME ap-
plication (46). ROS, generated by NADPH oxidases, also
induce the formation of ROS in mitochondria, which, in turn,
stimulate radical production in the cytosol, thus inducing a
self-sustaining vicious cycle (17, 38, 40). A targeted phar-
macological intervention using substances with an antioxi-
dant potential specific for mitochondrial ROS disrupts this
feed-forward cycle efficiently (44).
This therapeutic approach corresponds to the endogenous
upregulation of SOD2 in the LV of animals treated with L-
NAME. The type 2 isoform of SOD, which is also known as
manganese superoxide dismutase (Mn-SOD), catalyzes the
formation of H2O2 from superoxide anions, specifically in the
mitochondria.
As a direct consequence of the RV radical load, the in-
duction of the cytokine TGF-beta is a key mechanism that is
responsible for the development of fibrosis and RV failure
(12, 27, 31).
In addition to RV fibrosis, which primarily affects ventric-
ular stiffness and thus diastolic filling, a higher degree of
oxidized Tm (oxTm) could be identified in RV of animals fed
L-NAME. The formation of DCB induced by oxidative stress
leads to a conformational change of Tmprotein, which directly
affects contractile function. However, the observed modifica-
tion of Tm in RV of L-NAME-fed animals is likely to be
responsible for the deterioration inRV systolic pressure aswell
as for the reduction in dp/dt max and dp/dt min (14, 15).
FIG. 7. Effects of L-NAMEon SOD2 expression and cell
shortening at a cellular level. (A) Representative immuno-
blots indicating SOD2 immunoreactivity in isolated cardio-
myocytes from untreated control cells (C), cells incubated for
24 h with L-NAME (L) and L-NAME plus actinomycin D
(L +A). SOD2 values were normalized to GAPDH levels. (B)
Densitometric analysis of immunoblot bands. SOD2 was
upregulated only in myocytes isolated from the LV. Data are
means – SD of n = 4 hearts. (C) Effect of L-NAME on cell
shortening. Cardiomyocytes were isolated separately from
the RV and LV of untreated rats and incubated with L-NAME
for 24 h. L-NAME led to a significant reduction in relative
cell shortening only in RVmyocytes. Data are means – SD of
n = 4 hearts. (D) Cell shortening of LV cardiomyocytes was
significantly reduced if myocytes were co-incubated with L-
NAME (L) and the translation inhibitor cycloheximide
(L +Chx), the transcription inhibitor actinomycin D (L+Act-
D), or the Sirt1 inhibitor Ex-527 (L +Ex-527). PD98059
(L +PD98059) did not have any effect on cell contraction.
Data are means – SD of n = 4 hearts. *p< 0.05 versus control.
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The missing upregulation of SODs in the RV together with
the accumulation of O2
- have also led to a selective increase
in peroxynitrite in the RV of animals fed L-NAME.
The intrinsically higher RV ONOO- concentration com-
pared with the LV conforms to the results obtained with
the DHE-based radical staining. The induction of the LV
TXNRD1 expression described is critically involved in the de-
toxification of ONOO- by making peroxiredoxin available.
The significant reduction in free radicals achieved by
tempol, therefore, also led to a normalization of the ONOO-
concentration in the RV in the LT group. Because both ROS
and NO are required for the formation of ONOO-, the in-
crease in peroxynitrite in the RV of the LC group could
possibly be explained by the stimulatory effect of captopril
on NO production. The inhibitory effect on the RAS, direct
antioxidative effects, and the increased formation of NO are
some of the protective properties of captopril that can gen-
erally contribute to a reduction in oxidative stress (9, 22). To
what extent the increased formation of ONOO- in the RV of
the LC group influences structural or functional remodeling
cannot be determined based on the current data. Furthermore,
the significance of ONOO- as an exclusively harmful com-
pound is in doubt, and its involvement in the maintenance of
the redox homeostasis and stress adaptation is the subject of
ongoing discussion (3, 19, 20).
The inability of the RV to appropriately adjust its antioxidant
capacity under pathophysiological conditions caused by L-
NAMEor an eNOSknockout led to an increase in the formation
of free radicals (DHE staining, MitoSox Red), an increased
percentage of oxTm, and a rise in the formation of peroxyni-
trite. The causes of the resultant cardiac dysfunction are based
on a structurally remodeled ventricle with a significantly in-
creased quantity of collagen and the impaired function of the
RV cardiomyocytes themselves. The restrictive components of
the cardiac symptoms led to an increase in the liver transami-
nases GOT/GPT via blood accumulation in the liver.
FIG. 8. Cardiac remodeling of the extracellular matrix. The mRNA expression for (A) transforming growth factor
beta1 (TGF-beta1), (B) collagen I, and (C) collagen III was analyzed in all four treatment groups separately for the RV and
LV using real-time reverse transcription polymerase chain reaction (RT-PCR). Rats were given pure drinking water (C), L-
NAME (L), L-NAME plus captopril (LC), and L-NAME plus tempol (LT). The expression of HPRT was used for
normalization. Data are means – SEM of n = 8 hearts. (D, E) The massive upregulation of collagen I and III in the RV of L-
NAME-fed animals (L) could be confirmed subsequently in histological sections with the help of Sirius Red staining. RV
fibrosis could be significantly reduced by captopril (LC group) or tempol (LT group). RV (septum): RV close to the septum
interventricularis. Data are means – SD of n = 5 hearts. *p < 0.05 versus control, #p < 0.05 versus L-NAME.
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The LV was able to critically elevate its antioxidant po-
tential by inducing PGC-1a and its downstream target Nrf-2
(10). Nrf-2 dependent genes, which include the cytoprotec-
tive proteins Gclc and TXNRD1 along with SOD2, prevented
both the structural remodeling and the impaired function of
the LVmyocardium (11, 18). The transcription of PGC-1a is,
in turn, regulated by Sirt1, the inhibition of which by Ex-527
led to a reduction in the cell shortening of LV isolated
myocytes as did the inhibition of transcription by actino-
mycin D (Act-D) and the inhibition of translation by Chx.
The previously described upregulation of SOD2 was pre-
vented by a blockade of this signaling pathway.
Both therapeutic interventions, captopril and tempol, had an
equally positive effect on the cardiac remodeling of the RV
independent of their antihypertensive efficiency. Moreover,
hydralazine with strong antihypertensive but no antioxidative
properties was unable to prevent the induction of the RV re-
modeling (6). These results support the conjecture that neither
the blood pressure nor an elevated afterload but rather ROS is
the cause of the RV symptoms. This situation is supported by
the results of the cell culture experiments that confirmed the
impaired adaptation mechanisms (reduced SOD2 expression)
and the resulting impaired function of the RV myocardium
independent of systemic influences and blood pressure.
To what extent the application of L-NAME affected the
pulmonary arterial pressure was not determined in this study.
Sekiguchi et al. compared the peripheral and pulmonary ar-
terial blood pressure in spontaneously hypertensive rats and
rats fed L-NAME (2 weeks, 50mg/100ml). Systemic hy-
pertension was recorded in both models. An increase in the
pulmonary arterial pressure could, however, only be diag-
nosed in the spontaneously hypertensive rats (SHR), while
the chronic application of L-NAME did not have any effect
on the pressure ratios in the pulmonary circulation system
(43). These results correspond to the expression pattern de-
scribed in this study for the natriuretic peptide ANP. The
increased afterload in the LV, associated with a moderate
hypertrophy, led to a significant increase in the LV ANP
expression. The lack of induction of ANP expression in the
RV myocardium indicates that the pressure conditions in the
pulmonary circulation are unchanged.
In light of this, the results of this study can be translated to
cardiac diseases that are associated with elevated oxidative
stress and, subsequently, can induce the development of RV
failure (10). Without itself being the starting point of the
symptoms, for the RV there is an elevated risk of being
secondarily damaged due to increased accumulation of ROS
during LV failure or LV infarction.
In summary, the results of this study show for the first time
that oxidative stress is a vastly greater risk factor for the RV
than for the LV. Molecular and cellular results indicate that
critical signaling pathways and key enzymes in the RV and
LV are activated and regulated in different ways, which may
lead to the development of targeted therapy against RV
failure. Indeed, our results suggest that the prognosis for RV
failure can be greatly improved by using ACE inhibitors with
high antioxidant capacity.
Materials and Methods
The investigation conforms the Guide for the Care and Use
of Laboratory Animals published by the USNational Institute
of Health (NIH Publication No. 85-23, revised 1996). The
study was approved by the local authorities for animal ex-
periments (V54-19c 2015 (I) GI 20/1 Nr. 58-2005).
Experimental model
Eighty-two 3-month-old female wistar rats were divided
into four groups and kept in individual cages. Animals had
free access to food and water ad libitum. Animals were as-
signed to receive L-NAME (7.5mg/day in drinking-water),
L-NAME plus captopril (5.0mg/day in drinking-water) (2),
L-NAME plus tempol (1.0mM in drinking-water) (5), L-
NAME plus hydralazine (5.0mg/day in drinking-water) (42),
or drinking-water only (age-matched control) for 28 days
(Supplementary Fig. S1A). As an alternative model for a
chronic deficiency in NO, 6-month-old female eNOS-/-
mice and their wild-type littermates were used.
The health status of the experimental animals was deter-
mined weekly using a ‘‘distress score’’ (33). Over the entire
experimental period, no animals died or had to be excluded
from the study based on the exclusion criteria.
Determination of the blood pressure and heart rate
Peak systolic blood pressure and heart rate were measured
weekly using the non-invasive tail-cuff method (TSE-Sys-
tems, 209000Series). Before the start of the study, the ani-
mals were adjusted to the experimental procedure over 1
week. The mean of 10 consecutive blood pressure readings
was obtained for each animal at weekly intervals.
RNA isolation and real-time RT-PCR
Total RNA was isolated from RV and LV using peqGold
TriFast (peqlab; Biotechnologie GmbH) according to the
manufacturer’s protocol. To remove genomic DNA con-
tamination, isolated RNA samples were treated with 1U
DNase/lg RNA (Invitrogen) for 15min at 37C. One lg of
total RNA was used in a 10 ll reaction to synthesize cDNA
using Superscript RNaseH Reverse Transcriptase (200U/lg
RNA; Invitrogen) and oligo dTs as primers. RT reactions
were performed for 50min at 37C. Real-time quantitative
PCR was performed using the MyiQ detection system (Bio-
Rad) in combination with the iTaq Universal SYBR Green
Real-Time PCR Supermix (Bio-Rad). Quantification was
performed as described earlier (32). Primer sequences are
listed in Supplementary Table S4.
Picrosirius red staining
Samples were embedded with Tissue-Tek (Sakura) and
sectioned in 10lm slices. Histological sections were fixed in
Bouin solution and subsequently stained in 0.1% (wt/vol)
Sirius Red solution (Sigma-Aldrich Chemie). Sections were
washed by 0.01N HCl, Aqua dest. and counterstained for
nuclei by Mayers hemalaun solution, washed with Aqua dest.
for 5min, and dehydrated with ethanol. Total collagen content
was quantified by digital image analysis using Leica Confocal
Software Lite Version (LCS Lite). The mean of n= 5 prepa-
rations was used to quantify the extent of interstitial fibrosis.
Measurement of superoxide
To perform DHE staining, cryosections of RV and LV
were incubated with DHE (dissolved in 1 X PBS) for 10min
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at 37C in a light-protected humidity chamber, then fixed with
Dako Fluorescent Mounting Medium (Dako, North America,
Inc.). Slides were then imaged by confocal microscopy (LSM
510 META; Carl Zeiss) using an excitation wavelength of
488 nm; emission was recorded at 540 nm (37).
Analysis was performed by digital image analysis using
Leica Confocal Software Lite Version (LCS Lite). The mean
fluorescence intensity of n = 5 ventricles was used to quantify
the extent of superoxide.
Mitochondrial ROS analysis
Formation of ROS in mitochondria was detected with
MitoSOX Red, a mitochondrial superoxide fluorescence in-
dicator. Briefly, isolated cardiomyocytes were incubated with
1 lM MitoSOX Red at 37C for 30min and then washed
twice for 10min in CCT medium. The loaded cells were
excited at 510 nm, and the emitted light was collected at
580 nm (1).
Detection of MDA using a TBARS Assay Kit
The formation of MDA was used as a well-established
indicator of oxidative stress in plasma samples. Shortly,
blood samples from treated and untreated rats were centri-
fuged (1500 g) at 4C for 15min to obtain plasma. One
hundred microliters sample was incubated with TBA under
acid conditions for 60min at 95C. Sample vials were then
placed on ice for 10min and centrifuged for 10min at 1600 g.
One hundred fifty microliters reaction mixture was measured
fluorometrically in duplicate at an excitation wavelength of
530 nm and an emission wavelength of 550 nm. The tests
were carried out using TBARS Assay Kit purchased from
Cayman Chemical Company.
Measurement of peroxynitrite
To estimate peroxynitrite formation in the RV and LV, we
measured peroxynitrite marker nitrotyrosine by ELISA
(components from Cayman Chemical) in ventricular ho-
mogenates as previously described (8, 16). Briefly, RV and
LV tissue samples were pulverized in liquid nitrogen, soni-
cated in 4· homogenization buffer, and centrifuged. Super-
natants were then incubated overnight with anti-nitrotyrosine
rabbit IgG and nitrotyrosine acetylcholinesterase tracer in
precoated (mouse anti-rabbit IgG) microplates followed by
development with Ellman’s reagent. Protein concentration of
the samples was measured by the bicinchoninic acid assay.
Western blot
Total protein was extracted from RV and LV using Cell
Lysis Buffer (10·) (Cell Signaling) according to the manu-
facturer’s protocol. Briefly, the homogenate was centrifuged at
14,000g at 4C for 10min and the supernatant was treatedwith
Laemmli buffer. Protein samples were loaded on NuPAGE
Bis-Tris Precast gels (10%; Life Technology) and, subse-
quently, transferred onto nitrocellulose membranes. Blots
were incubated with one of the following antibodies: anti-Tm
purchased from Sigma-Aldrich (product T9283) or anti SOD2
purchased fromMerck Millipore (product 06-984). Secondary
antibodies [horseradish peroxidase (HRP)-conjugated] di-
rected against rabbit IgG or mouse IgG were purchased from
Sigma-Aldrich, respectively Affinity Biologicals.
Hemodynamic measurements
Heart function was measured in closed-chest spontane-
ously breathing rats anesthetized with thiopental sodium
(Trapanal 60mg/kg i.p.) using ultraminiature catheter
pressure transducers (3 F; Millar Instruments, Inc.). Briefly,
the rats were placed in supine position on a heating pad and
the RV catheter (model SPR-291) was inserted into the right
jugular vein and advanced into the RV via the right atrium.
Heart rate, RV systolic pressure, and the rate in rise and fall of
ventricular pressure (RV dp/dt) were recorded continuously
on a PC at a sampling rate of 1 kHz using PowerLab 16/30
with Quad Bridge Amp and LabChart 7 software (all
ADInstruments) for 10–15min.
Langendorff perfusion
To analyze LV function, conditioned rats were anaes-
thetized by isoflurane and killed by cervical dislocation.
Thereafter, hearts were rapidly excised and the aorta was
cannulated for retrograde perfusion with a 16-gauge needle
connected to a Langendorff perfusion system. A polyvinyl
chloride balloon was inserted into the LV through the mitral
valve and held in place by a suture tied around the left atrium.
The other end of the tubing was connected to a pressure
transducer for continuous measurement of LV pressure, dp/dt
max, and dp/dt min (41).
Measurements of transaminases (GOT/GPT)
in blood plasma
To quantify GOT/GPT levels in plasma samples, the rat
aspartate aminotransferase ELISA Kit from Bioassay Tech-
nology Laboratory was used. The test procedure was per-
formed according to the manufacturer’s instructions. Briefly,
blood samples from treated and untreated rats were centri-
fuged (1500 g) for 15min to obtain plasma. Forty microliters
of plasma were then incubated in duplicate with 10ll biotin-
labeled anti GOT/GPT antibodies and streptavidin-HRP. The
liquid turned blue after adding chromogen solution and yel-
low with the effect of acid. The color intensity correlates
positively with the concentration of GOT/GPT.
Isolation and cultivation of cardiomyocytes
from the RV and LV
Heart muscle cells from the RV and LVwere isolated from
3-month-old male wistar rats. Briefly, hearts were excised,
transferred rapidly to ice-cold saline, and mounted on the
cannula of a Langendorff perfusion system. Heart perfusion and
subsequent steps were performed at 37C. First, hearts were
perfused in a non-circulating manner for 5min at 10ml/min.
Thereafter, perfusion was continued with recirculation using
50ml perfusate supplemented with 0.06% (w/v) crude colla-
genase and 25lM CaCl2 at 5ml/min for 25min. Then, the RV
was dissected from the LV and septum and processed separately
in the next few steps (47).
Isolated cardiomyocytes were then incubated with L-
NAME (1.0mM; Sigma-Aldrich, product N5751) alone and
in the presence of cyclohexemide (35.0 lM; Sigma-Aldrich,
product C-7698), actinomycin D (5.0 lM; Sigma-Aldrich,
product A5142), Ex-527 (10.0 lM; Sigma-Aldrich, product
E7034), or PD98059 (10.0 lM; Merck Millipore, product
513000) for 24 h.
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Determination of cell contraction
Cell shortening was measured as described earlier in
greater detail (47). Briefly, isolated cardiomyocytes were
allowed to contract at room temperature and analyzed using a
cell-edge detection system. Cells were stimulated via two
AgCl electrodes with biphasic electrical stimuli composed of
two equal but opposite rectangular 50-V stimuli of 0.5ms
duration. Each cell was stimulated for 1min at a frequency of
2.0Hz. Every 15 s contractions were recorded. The mean of
these four measurements was used to define the cell short-
ening of a given cell. Cell lengths were measured via a line
camera (data recording at 500Hz). Data are expressed as cell
shortening normalized to diastolic cell length (dL/L [%]).
Statistics
Data are expressed as indicated in the legends. ANOVA
and the Student–Newman–Keuls test for post hoc analysis
were used to analyze experiments in which more than one
group was compared. In cases in which two groups were
compared, Student’s t-test or Mann–Whitney test was em-
ployed, depending on a normal distribution of samples (Le-
vene test). p < 0.05 was regarded as significant.
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Abbreviations Used
ACE¼ angiotensin-converting enzyme
Act-D¼ actinomycin D
ANP¼ atrial natriuretic peptide
BNP¼ brain natriuretic peptide
bpm¼ beats per minute
BW¼ body weight
C¼ control group
Chx¼ cyclohexemide
DCB¼ disulphide cross-bridges
DHE¼ dihydroethidium
eNOS-=-¼ homozygous eNOS knockout
Gclc¼ glutamate-cysteine ligase, catalytic subunit
GOT/GPT¼ glutamate-oxaloacetate transaminase/glutamate-
pyruvate transaminase
Gpx1¼ glutathione peroxidase 1
H2O2¼ hydrogen peroxide
HADHA¼ hydroxyacyl-CoA dehydrogenase, alpha
subunit
HPRT¼ hypoxanthine-guanine
phosphoribosyltransferase
HRP¼ horseradish peroxidase
L¼L-NAME group
LC¼L-NAME/captopril group
LT¼L-NAME/tempol group
LV¼ left ventricle
LVDP¼ left ventricular developed pressure
LW¼ liver wet weight
MHC-a¼myosin heavy chain alpha
MHC-b¼myosin heavy chain beta
NO¼ nitric oxide
NOX2¼ cytochrome b-245 heavy chain
Nrf(-1,-2)¼ nuclear respiratory factor (-1, -2)
ONOO-¼ peroxynitrite
oxTm¼ oxidized tropomyosin
P22phox¼ cytochrome b-245 light chain
PGC-1a¼ peroxisome proliferator-activated receptor
gamma coactivator 1-alpha
RAAS¼ renin-angiotensin-aldosterone system
ROS¼ reactive oxygen species
RT-PCR¼ reverse transcription polymerase chain
reaction
RV¼ right ventricle
RVEDP¼ right ventricular end-diastolic pressure
RVSP¼ right ventricular systolic pressure
SHR¼ spontaneously hypertensive rats
SOD (1-3)¼ superoxide dismutase (1-3)
TGF-beta1¼ transforming growth factor beta1
Tm¼ tropomyosin
TXNRD1¼ thioredoxin reductase 1
UCP(-2,-3)¼mitochondrial uncoupling protein (-2, -3)
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